LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Reagent Technology Licensed to Olympus Diagnostica

By Labmedica staff writers
Posted on 20 Jan 2005
A worldwide nonexclusive license to new technology for mixing reagents using surface acoustic waves has been granted to Olympus Diagnostica (Hamburg, Germany) by Advalytix AG (Brunnthal, Germany).

Advalytix pioneered the use of surface acoustic waves (SAW) for the manipulation and agitation of small liquid volumes. The waves induce quasi-chaotic streaming patterns that lead to the efficient agitation of liquids with volumes ranging from several hundred microliters down to a few nanoliters. The agitation method is noninvasive and prevents the risks of cross-contamination and carry-over. SAW technology has been commercially available in a hybridization station of Advalytix called SlideBooster, targeted at the research and development market. Now SAW will be introduced to the diagnostics market.

Olympus Diagnostica will integrate the technology into its product line of routine laboratory analyzers. "This technology will enable Olympus Diagnostica to significantly improve the next generation of analyzers,” noted Dr. Helmut Kohler, CEO of Olympus Diagnostica. Olympus Diagnostica is a systems provider for in vitro diagnostics in clinical chemistry, electrophoresis, and transfusion testing. Under the terms of the agreement, Olympus Diagnostica will provide an upfront payment, milestone payments, and royalties on the sales of instruments.



Related Links:
Olympus Diagnostica
Advalytix

Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Homocysteine Quality Control
Liquichek Homocysteine Control
Automatic CLIA Analyzer
Shine i9000

Latest Industry News

WHX Labs Dubai to Gather Global Experts in Antimicrobial Resistance at Inaugural AMR Leaders’ Summit
20 Jan 2005  |   Industry

BD and Penn Institute Collaborate to Advance Immunotherapy through Flow Cytometry
20 Jan 2005  |   Industry

Abbott Acquires Cancer-Screening Company Exact Sciences
20 Jan 2005  |   Industry